{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T08:22:57Z","timestamp":1781511777527,"version":"3.54.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.msard.2016.03.005","type":"journal-article","created":{"date-parts":[[2016,4,3]],"date-time":"2016-04-03T08:43:02Z","timestamp":1459672982000},"page":"145-150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Re-evaluating the incidence of natalizumab-associated progressive multifocal leukoencephalopathy"],"prefix":"10.1016","volume":"8","author":[{"given":"Julian","family":"Borchardt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph R.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.msard.2016.03.005_bib1","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1177\/1352458514526945","article-title":"High discontinuation rate of natalizumab in JC virus seropositive patients due to significant anxiety and safety feelings","volume":"20","author":"Alroughani","year":"2014","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2016.03.005_bib333","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/ana.23893","article-title":"JC virus antibody status underestimates infection rates","volume":"74","author":"Berger","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2016.03.005_bib2","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2016.03.005_bib3","doi-asserted-by":"crossref","unstructured":"Bozic, C., Richman, S., Plavina, T., et al., 2012. Anti-JCV Antibody Prevalence in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Natalizumab: Baseline Results of STRATIFY-2 (S41.002). AAN 64th Annual Meeting, 2012, S41.002. \u3008http:\/\/www.neurology.org\/cgi\/content\/meeting_abstract\/78\/1_MeetingAbstracts\/S41.002\u3009.","DOI":"10.1212\/WNL.78.1_MeetingAbstracts.S41.002"},{"key":"10.1016\/j.msard.2016.03.005_bib4","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/ene.12304","article-title":"Anti\u2013JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial","volume":"21","author":"Bozic","year":"2014","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2016.03.005_bib5","first-page":"P1123","article-title":"The incidence of PML in natalizumab long-term safety programs is comparable to postmarketing incidence","author":"Butzkueven","year":"2011","journal-title":"ECTRIMS-ACTRIMS"},{"key":"10.1016\/j.msard.2016.03.005_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2013-306936","article-title":"Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results","volume":"85","author":"Butzkueven","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2016.03.005_bib7","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1177\/1352458514531843","article-title":"Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?","volume":"20","author":"Cutter","year":"2014","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2016.03.005_bib9","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S1474-4422(11)70149-1","article-title":"Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring","volume":"10","author":"Kappos","year":"2011","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2016.03.005_bib10","first-page":"P976","article-title":"Assessment of Baseline Characteristics, Treatment Efficacy, and Serious Adverse Events among Natalizumab-Treated MS Patients with Prior Immunosuppressant Use","author":"Kappos","year":"2011","journal-title":"ECTRIMS-ACTRIMS"},{"key":"10.1016\/j.msard.2016.03.005_bib11","unstructured":"Keller-Stanislawski B., 2011. Natalizumab (Tysabri) and PML \u2013 the current figures. Transatlantic Workshop on Drug-related Progressive Multifocal Leukoencephalopathy, London, Jul. 2011. \u3008http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Presentation\/2011\/07\/WC500109631.pdf\u3009, (accessed December 2015)."},{"key":"10.1016\/j.msard.2016.03.005_bib12","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jcv.2013.02.002","article-title":"A second-generation ELISA (STRATIFY JCV\u2122 DxSelect\u2122) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification","volume":"57","author":"Lee","year":"2013","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.msard.2016.03.005_bib13","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1136\/jnnp-2013-306573.181","article-title":"Does JCV antibody positivity encourage cessation of natalizumab therapy in multiple sclerosis?","volume":"84","author":"Lonergan","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2016.03.005_bib14","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1212\/WNL.0000000000000541","article-title":"Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study","volume":"83","author":"O\u2019Connor","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2016.03.005_bib15","doi-asserted-by":"crossref","unstructured":"Ongagna, J., Fleury, M., Collongues, N., et al., 2013. Therapeutic Decision after JC Virus Testing in a Cohort of Patients Treated with Natalizumab. AAN 65th Annual Meeting, 2013, P01.184. \u3008http:\/\/www.neurology.org\/cgi\/content\/meeting_abstract\/80\/1_MeetingAbstracts\/P01.184\u3009.","DOI":"10.1212\/WNL.80.7_supplement.P01.184"},{"key":"10.1016\/j.msard.2016.03.005_bib16","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1177\/1352458513505353","article-title":"JC-virus seroconversion in multiple sclerosis patients receiving natalizumab","volume":"20","author":"Outteryck","year":"2014","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2016.03.005_bib17","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ana.24286","article-title":"Anti\u2013JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Plavina","year":"2014","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2016.03.005_bib18","doi-asserted-by":"crossref","unstructured":"Schwab, N., Schneider-Hohendorf, T., Pignolet, B., et al., 2015. PML risk stratification using anti-JCV antibody index and L-selectin. Mult Scler, published Online before print on 2nd Oct. 2015. http:\/\/dx.doi.org\/10.1177\/1352458515607651","DOI":"10.1177\/1352458515607651"},{"key":"10.1016\/j.msard.2016.03.005_bib222","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00415-015-7655-1","article-title":"Body weight-based natalizumab treatment in adult patients with multiple sclerosis","volume":"262","author":"Tanaka","year":"2015","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2016.03.005_bib19","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1177\/1352458512439238","article-title":"Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision","volume":"18","author":"Tur","year":"2012","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2016.03.005_bib20","unstructured":"TY-PAN-0597(17), 2014. Biogen. TYSABRI (natalizumab) Benefit\/Risk Update & PML Risk Stratification. Date of preparation: Dec. 2014. \u3008http:\/\/www.slideshare.net\/gavingiovannoni\/natalizumab-benefit-risk-update-q4-2014\u3009, (accessed December 2015)."},{"key":"10.1016\/j.msard.2016.03.005_bib21","unstructured":"TY-US-0102(6), 2015. Biogen. TYSABRI (natalizumab): PML Incidence in Patients Receiving TYSABRI. 24th Sept. 2015. \u3008https:\/\/medinfo.biogen.com\/medinfo\u3009, (accessed November 2015)."},{"key":"10.1016\/j.msard.2016.03.005_bib22","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/ana.24345","article-title":"Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab","volume":"77","author":"Villar","year":"2015","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2016.03.005_bib23","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.tips.2015.09.006","article-title":"PML: The Dark Side of Immunotherapy in Multiple Sclerosis","volume":"36","author":"Warnke","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.msard.2016.03.005_bib24","article-title":"Medicine\u2019s dangerous guessing game: different methods of weighing the risks and benefits of medical treatments lead to varying conclusions about their safety","author":"Winstein","year":"2009","journal-title":"Wall Str. J."},{"key":"10.1016\/j.msard.2016.03.005_bib25","doi-asserted-by":"crossref","unstructured":"Zhovtis Ryerson, L., Frohman, T.C., Foley, J., et al., 2016. Extended interval dosing of natalizumab in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 10.1136\/jnnp-2015-312940.","DOI":"10.1136\/jnnp-2015-312940"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034816300244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034816300244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:39:08Z","timestamp":1761899948000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034816300244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":26,"alternative-id":["S2211034816300244"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2016.03.005","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Re-evaluating the incidence of natalizumab-associated progressive multifocal leukoencephalopathy","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2016.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}